Outlook Therapeutics (OTLK) News Today $1.44 +0.05 (+3.60%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ATX Ahead: 2025 Economic Outlook event coming in JanuaryDecember 18 at 4:06 PM | bizjournals.comOutlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial LaunchDecember 13, 2024 | marketwatch.comOutlook Therapeutics® Streamlines OperationsDecember 13, 2024 | globenewswire.comBTIG Reaffirms Their Buy Rating on Outlook Therapeutics (OTLK)December 11, 2024 | markets.businessinsider.comOutlook Therapeutics announces NICE recommendation of LYTENAVADecember 4, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDDecember 4, 2024 | globenewswire.comOutlook Therapeutics® Announces Executive Leadership TransitionDecember 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLKDecember 2, 2024 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)November 28, 2024 | markets.businessinsider.comOutlook Therapeutics Trial of Eye Disease Treatment Misses Key EndpointNovember 28, 2024 | marketwatch.comOutlook Therapeutics reports preliminary results from Norse Eight trialsNovember 28, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical TrialNovember 28, 2024 | markets.businessinsider.comOutlook plunges as lead asset fails in wet AMD studyNovember 28, 2024 | msn.comWhy Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?November 27, 2024 | benzinga.comGreat Point Partners LLC Sells 408,482 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)Great Point Partners LLC trimmed its holdings in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 24.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,293,028 shares of the company's stock aNovember 27, 2024 | marketbeat.comOutlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical TrialNovember 27, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Buy" from BrokeragesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has received a consensus rating of "Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objectNovember 24, 2024 | marketbeat.comOutlook Therapeutics® to Present at the Guggenheim Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comCautious Outlook on United Therapeutics Amid Revenue Growth and Competitive PressuresNovember 1, 2024 | markets.businessinsider.comULM College of Business and Social Sciences to host Outlook Summit at Bayou Pointe Event Center on November 8October 29, 2024 | msn.comPositive Outlook on Viking Therapeutics Driven by Promising VK2735 Obesity ProgramOctober 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Poised to Capitalize on Market Opportunities with LYTENAVA Amidst Industry ShiftsOctober 19, 2024 | markets.businessinsider.comOutlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG ResearchBTIG Research reiterated a "buy" rating and set a $50.00 target price on shares of Outlook Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comOutlook Therapeutics® Participates in a Virtual Investor CEO Connect SegmentOctober 17, 2024 | finance.yahoo.comEconomic Outlook Conference will “Re-Imagine” the future of the Ohio ValleyOctober 12, 2024 | msn.comOutlook down? Microsoft confirms issues with email service, but a fix is now hereOctober 12, 2024 | yahoo.comWeekend Weather Outlook: Tri-Cities heat up again for a warm, sunny weekendOctober 12, 2024 | yahoo.comIs Outlook down? Thousands report Microsoft 365 issuesOctober 12, 2024 | news.yahoo.comOUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 11, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by BrokeragesShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among analysOctober 5, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) CFO Purchases $28,450.00 in StockOctober 1, 2024 | insidertrades.comOutlook: How to add or remove birthdays from your calendarSeptember 28, 2024 | yahoo.comRevenera’s Monetization Monitor 2025 Outlook Highlights Opportunities to Drive ProfitabilitySeptember 26, 2024 | finance.yahoo.com5 Reasons Why I Schedule My Outlook EmailsSeptember 26, 2024 | yahoo.comViking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of DataSeptember 25, 2024 | seekingalpha.comMicrosoft Outlook: Best tips and tricks I use to manage my inbox efficientlySeptember 25, 2024 | msn.comGreat Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)Great Point Partners LLC lifted its stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 15.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,701,510 shares of the company's stock after buying an additional 221,5September 24, 2024 | marketbeat.comManage Your Outlook Attachments Like a Pro with These 8 TipsSeptember 23, 2024 | msn.comIntegrated Financial Technologies to Sponsor Auto Finance Summit Market Outlook SessionSeptember 23, 2024 | finance.yahoo.comNielsenIQ Mid-Year Consumer Outlook: Guide to 2025 Reveals Catalysts to Change in Key Verticals Across IndustriesSeptember 23, 2024 | finance.yahoo.comAtlantic Tropical Outlook: South may be impacted by a Gulf stormSeptember 21, 2024 | msn.comThe New Outlook for Windows Isn't Worth Using: 8 Improvements It NeedsSeptember 19, 2024 | msn.comWindows’ new Outlook app: 4 key details you absolutely need to knowSeptember 19, 2024 | msn.comEvilginx Gmail And Outlook Attacks Can Bypass 2FA, Security Expert WarnsSeptember 19, 2024 | forbes.comThird-party email apps are about to lose access to Outlook emailsSeptember 17, 2024 | msn.comOutlook Therapeutics® to Participate in the Virtual Investor Closing Bell SeriesSeptember 16, 2024 | globenewswire.comOutlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference SeriesSeptember 13, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from BrokeragesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target amoSeptember 10, 2024 | marketbeat.comBuy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/LytenavaSeptember 5, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical TrialSeptember 4, 2024 | globenewswire.com Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.000.61▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼14▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cabaletta Bio News Today Vaxart News Today Enanta Pharmaceuticals News Today InflaRx News Today Applied Therapeutics News Today Protalix BioTherapeutics News Today Cassava Sciences News Today Aligos Therapeutics News Today Editas Medicine News Today Inventiva News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
